Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Journal of Neuroendocrinology|October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumoursRodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.Neuroendocrinology|July 30, 2020
A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine TumorsMagnus Kjellman, Ulrich Knigge, Staffan Welin, et al.The Lancet. Oncology|October 15, 2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trialBernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyKjell Magne Tveit, Tormod Guren, Bengt Glimelius, et al.International Journal of Cancer|February 5, 2026
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomasSiren Morken, Seppo W Langer, Geir Olav Hjortland, et al.Annals of Surgery|February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.Lancet (London, England)|March 25, 2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialBernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.British Journal of Cancer|May 17, 2025
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 studyHalfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, et al.Frontiers in Oncology|March 7, 2022
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal CancerEmerik Osterlund, Ari Ristimäki, Soili Kytölä, et al.Acta Oncologica (Stockholm, Sweden)|May 3, 2024
Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)Sampsa Kinos, Helga Hagman, Päivi Halonen, et al.Pageof 10